CHARLESTON, S.C.--(BUSINESS WIRE)--Plasma Technologies LLC (PlasmaTech), a plasma biologics technology company, announced that its novel human plasma fractionation process has been shown to achieve a ...
The starting material for virtually all pharmaceuticals and biologics is a synthetic or chemical. Human plasma-derived therapies are one of the few exceptions. A number of fragile proteins can be ...
IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced today that Grifols’ North Fractionation Facility in Clayton, N.C., was named the International Society for Pharmaceutical ...
ADMA Biologics receives FDA approval for a process enhancing plasma production yields by 20%, boosting growth and capacity for its products. ADMA Biologics, Inc. has announced the U.S. FDA approval of ...
The plasma fractionation market is projected to reach US$ 40,731.98 million by 2028 from US$ 26,575.83 million in 2021; it is expected to grow at a CAGR of 6.3% during 2021-2028. According to the ...
ndonesia is set to host its first-ever plasma fractionation plant in Karawang, West Java, which is poised to become the largest such facility in Southeast Asia. This milestone marks a major step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results